In prostate cancer liver metastasis models driven by HoxB13, repeated systemic SCORT‐Cas13d‐gHoxB13 treatment significantly decreases HoxB13 expression, reduces metastasis, and extends mouse survival. This evidence concerns the gene HOXB13 and prostate cancer.